🔗 Share this article

Ex-government leader Sunak has reinforced his call for a targeted examination protocol for prostate cancer.

In a recent conversation, he expressed being "certain of the immediate need" of introducing such a system that would be economical, feasible and "protect innumerable lives".

His comments emerge as the British Screening Authority reevaluates its determination from the previous five-year period against recommending routine screening.

News sources suggest the committee may continue with its current stance.

Athlete Contributes Support to Campaign

Gold medal cyclist Sir Hoy, who has late-stage prostate cancer, wants younger men to be tested.

He suggests decreasing the eligibility age for accessing a PSA blood test.

At present, it is not automatically provided to healthy individuals who are under 50.

The PSA test remains debated however. Levels can elevate for causes other than cancer, such as infections, leading to incorrect results.

Opponents argue this can result in needless interventions and adverse effects.

Focused Testing Initiative

The recommended examination system would focus on males between 45 and 69 with a family history of prostate cancer and black men, who experience increased susceptibility.

This population comprises around 1.3 million individuals males in the United Kingdom.

Organization calculations indicate the system would cost £25 million per year - or about eighteen pounds per individual - akin to bowel and breast cancer testing.

The projection involves 20% of eligible men would be contacted each year, with a nearly three-quarters participation level.

Clinical procedures (scans and biopsies) would need to increase by almost a quarter, with only a moderate growth in medical workforce, based on the study.

Medical Community Reaction

Various healthcare professionals are sceptical about the value of screening.

They argue there is still a risk that individuals will be medically managed for the condition when it is not absolutely required and will then have to live with side effects such as urinary problems and impotence.

One leading urology professional commented that "The challenge is we can often detect conditions that doesn't need to be addressed and we risk inflicting harm...and my apprehension at the moment is that negative to positive equation needs adjustment."

Individual Perspectives

Individual experiences are also influencing the conversation.

A particular instance features a man in his mid-sixties who, after requesting a PSA test, was diagnosed with the cancer at the time of fifty-nine and was informed it had metastasized to his hip region.

He has since experienced chemical therapy, radiotherapy and hormonal therapy but remains incurable.

The man advocates screening for those who are genetically predisposed.

"This is crucial to me because of my children – they are in their late thirties and early forties – I want them tested as promptly. If I had been screened at fifty I am confident I wouldn't be in the circumstances I am now," he stated.

Future Steps

The National Screening Committee will have to assess the data and arguments.

While the latest analysis indicates the implications for personnel and capacity of a screening programme would be achievable, opposing voices have argued that it would take diagnostic capabilities away from individuals being treated for other conditions.

The current discussion underscores the complex balance between early detection and potential excessive intervention in prostate cancer treatment.